Shattuck Labs, Inc. Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss
Shattuck Labs, Inc. (STTK) had Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss of $1.33 million as of 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss · last filed 2022-11-09
- 2022-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $1.33M.
- 2022-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $1.11M.
- 2022-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $527.00K.
- 2021-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $560.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss |
|---|---|
| 2022-09-30 | $1.33M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $1.11M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $527.00K 10-Q · filed 2022-05-12 |
| 2021-12-31 | $560.00K 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |